Compare NIM & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NIM | FATE |
|---|---|---|
| Founded | 1992 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.7M | 121.1M |
| IPO Year | N/A | 2013 |
| Metric | NIM | FATE |
|---|---|---|
| Price | $9.29 | $1.08 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $3.92 |
| AVG Volume (30 Days) | 35.4K | ★ 1.2M |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 3.46% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,137,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.28 | $0.66 |
| 52 Week High | $9.74 | $1.99 |
| Indicator | NIM | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 48.15 | 44.42 |
| Support Level | $9.20 | $1.02 |
| Resistance Level | $9.37 | $1.19 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 45.00 | 29.11 |
Nuveen Select Maturities Municipal Fund is a diversified closed-end management investment company. Its primary investment objective is to provide current income exempt from regular federal income tax, consistent with the preservation of capital. Its secondary investment objective is to enhance portfolio value relative to the municipal bond market through investments in tax-exempt municipal obligations that are underrated or undervalued, or that represent municipal market sectors that are undervalued.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.